Pancreatic Cancer
A Phase 3 Randomized, Open-Label Study Of Atebimetinib in Combination With Modified Gemcitabine And Nab-Paclitaxel Regimen Versus the Standard Gemcitabine And Nab-Paclitaxel Regimen For The Treatment Of Patients With Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
- Details
ClinicalTrials.gov ID:
NCT07562152
Diagnosis Type:
NA
USOR Number:
- Address
,
P: